Amanote Research
Register
Sign In
Pmu26 - Budget Impact Analysis of Intravenous Biosimilars Compared With Intravenous Originators and Subcutaneous Products
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.1862
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
Y Jang
A Byrne
F Toron
S Yoon
Publisher
Elsevier BV
Related search
Pcn75 - Budget Impact Model of Subcutaneous Trastuzumab Compared With Intravenous Trastuzumab on the Treatment of Her-2 Positive Breast Cancer in the Brazilian Private Healthcare System
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pharmacokinetics of Levofloxacin Following Intravenous and Subcutaneous Administration in Sheep
Asian Journal of Animal and Veterinary Advances
Animal Science
Zoology
Veterinary
Oral, Subcutaneous, and Intravenous Pharmacokinetics of Ondansetron in Healthy Cats
Journal of Veterinary Pharmacology and Therapeutics
Veterinary
Pharmacology
Bone Marrow Infusions: Intratibial and Intravenous Routes Compared
BMJ
Ultrasonography Compared With Intravenous Urography in the Investigation of Adults With Haematuria.
BMJ
Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer
JAMA Oncology
Cancer Research
Oncology
The Absorption and Excretion of Penicillin Following Continuous Intravenous and Subcutaneous Administration
Journal of Clinical Investigation
Medicine
Resource Utilization and Cost Saving Analysis of Subcutaneous Versus Intravenous Trastuzumab in Early Breast Cancer Patients
Oncotarget
Oncology
Subcutaneous or Intravenous Heparin in Treatment of Deep Vein Thrombosis
BMJ
